Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MediWound Ltd. - Ordinary Shares (NQ:MDWD)

12.97 -0.85 (-6.15%)
Delayed Quote Updated: 4:00 PM EST, Nov 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MediWound Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
MediWound (MDWD) Q3 2026 Earnings Call Transcript ↗
Phase III readout timing and supply constraints dominate the call. 
Via The Motley Fool
Topics Earnings
News headline image
What MediWound (MDWD) Said on Its Q3 Earnings Call ↗
MediWound (NASDAQ:MDWD) reported lower third-quarter revenue and a wider net loss as it increased spending on its late-stage EscharEx trial, while executives said manufacturing constraints continue to... 
Via MarketBeat
Topics Earnings
News headline image
MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares
From MediWound Ltd.
Via GlobeNewswire
MediWound Ltd. (NASDAQ:MDWD) Q1 2026: Revenue Miss but Narrower Loss, Full-Year Outlook Intact ↗
Via Chartmill
MediWound Ltd. (NASDAQ:MDWD) Reports Q4 2025 Revenue Miss Despite Pipeline Progress ↗
Via Chartmill
News headline image
MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report Third Quarter 2026 Financial Results
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
From MediWound Ltd.
Via GlobeNewswire
News headline image
Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound (MDWD) Q2 2026 Earnings Call Transcript ↗
EscharEx advances Phase III enrollment while manufacturing facility nears regulatory completion. 
Via The Motley Fool
Topics Earnings
News headline image
MediWound Q2 Earnings Call Highlights ↗
MediWound (NASDAQ:MDWD) reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, as the company continued investing in its Phase III EscharEx chronic-wound program... 
Via MarketBeat
Topics Earnings
News headline image
MediWound Q2 2026 Earnings Call: Complete Transcript ↗
MediWound (NASDAQ:MDWD) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts... 
Via Benzinga
Topics Earnings
News headline image
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report Second Quarter 2026 Financial Results
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound (MDWD) Q1 2026 Earnings Transcript ↗
MediWound (MDWD) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
MediWound Q1 Earnings Call Highlights ↗
MediWound (NASDAQ:MDWD) reported a wider first-quarter loss and lower revenue compared with the prior-year period, while management reaffirmed its 2026 revenue outlook and said it continued to advance... 
Via MarketBeat
Topics Earnings
News headline image
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report First Quarter 2026 Financial Results
From MediWound Ltd.
Via GlobeNewswire
News headline image
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Files Annual Report on Form 20-F
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound (MDWD) Q4 2025 Earnings Call Transcript ↗
MediWound (MDWD) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present at Upcoming Investor Conferences
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
From MediWound Ltd.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.